Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response’s assessed claim (“Felbatol is associated with a marked increase in aplastic anemia”) is directly supported by the label Boxed Warning stating Felbatol use is associated with a marked increase in the incidence of aplastic anemia, including >100-fold incidence versus untreated.
Category Scores
Accurate Statements
Felbatol is associated with a marked increase in aplastic anemia.
Boxed Warning (1), Aplastic Anemia: “THE USE OF FELBATOL (felbamate) IS ASSOCIATED WITH A MARKED INCREASE IN THE INCIDENCE OF APLASTIC ANEMIA.” Also: “AMONG FELBATOL TREATED PATIENTS, APLASTIC ANEMIA … occurs at an incidence that may be more than a 100 fold greater….”
supported
Matches the Boxed Warning language regarding marked increase in incidence of aplastic anemia.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The response accurately reflects a boxed warning statement about aplastic anemia risk; it does not add unsupported or incorrect guidance.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement